Heart Failure Food Intervention Trial: Impact of a Guideline-based Nutrition Digital Tool in Heart Failure Patient Clinical Outcomes

Laborértékek

• • Patients with certain patient history (cognitive disabilities) and end stage renal or metastatic cancer diagnosis
  • Patients with active drug/substance use. Patients with heart failure who have active substance use are excluded from the study. HF patients with substance use require additional monitoring and follow up due to potential severe withdrawal symptoms, acute HF exacerbation and drug overdose or medication errors. Standard protocol includes additional monitor vital signs (e.g., blood pressure, heart rate) and HF symptoms (e.g., edema, dyspnea), and performing regular laboratory tests (e.g., renal function, electrolytes) which is beyond the clinical and logistical capabilities of this study.

• 18-89 years old at time of enrollment
• Any type of Heart failure diagnosis (e.g., I50.x) between 1/1/2023-present
• Recent hospital admission (within a year)
• Race/ethnicity: All race/ethnic groups
• Location: patients have been treated in the Greater East Bay division and Greater Silicon Valley division areas.
• Patients with have at least 1 office/outpatient visit with a primary care physician or cardiologist visit before index date